Compare IPI & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | GLSI |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.0M | 372.0M |
| IPO Year | 2007 | 2020 |
| Metric | IPI | GLSI |
|---|---|---|
| Price | $37.43 | $25.50 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 396.9K | 126.7K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $298,328,000.00 | N/A |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.09 | ★ N/A |
| Revenue Growth | ★ 17.13 | N/A |
| 52 Week Low | $22.55 | $7.78 |
| 52 Week High | $50.34 | $34.10 |
| Indicator | IPI | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 53.61 |
| Support Level | $37.00 | $21.20 |
| Resistance Level | $49.06 | $30.02 |
| Average True Range (ATR) | 2.94 | 1.85 |
| MACD | -0.89 | 0.39 |
| Stochastic Oscillator | 5.38 | 74.41 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.